Development, characterization, and toxicity evaluation of amphotericin B–loaded gelatin nanoparticles

Gallis, 1990, Amphotericin B: 30 years of clinical experience, Rev Infect Dis, 12, 308, 10.1093/clinids/12.2.308

Kleinberg, 2006, What is the current and future status of conventional amphotericin B?, Int J Antimicrob Agents, 27S, S12, 10.1016/j.ijantimicag.2006.03.013

Boswell, 1998, AmBisome (liposomal Amphotericin B): a comparative review, J Clin Pharmacol, 38, 583, 10.1002/j.1552-4604.1998.tb04464.x

Lincopan, 2005, Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments, J Antimicrob Chemother, 55, 727, 10.1093/jac/dki064

Vieira, 2001, Synthetic bilayer fragments for solubilization of amphotericin B, J Colloid Interface Sci, 244, 427, 10.1006/jcis.2001.7975

Nahar, 2006, Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives, Crit Rev Ther Drug Carrier Syst, 23, 259, 10.1615/CritRevTherDrugCarrierSyst.v23.i4.10

Venier-Julienne, 1996, Preparation, purification and morphology of polymeric nanoparticles as drug carriers, Pharm Acta Helv, 71, 121, 10.1016/0031-6865(95)00059-3

Espuelas, 2003, Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice, J Antimicrob Chemother, 52, 419, 10.1093/jac/dkg351

Espuelas, 1997, Poly (e-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity, Int J Pharm, 158, 19, 10.1016/S0378-5173(97)00194-4

Tiyabbonchai, 2007, Formulation and characterization of Amphotericin B–chitosan–dextran sulfate nanoparticles, Int J Pharm, 329, 142, 10.1016/j.ijpharm.2006.08.013

Lee, 2001, Biomedical applications of collagen, Int J Pharm, 221, 1, 10.1016/S0378-5173(01)00691-3

Narayami, 1994, Controlled release of anticancer drug methotrexate from biodegradable gelatin microspheres, J Microencapsul, 11, 69, 10.3109/02652049409040439

Cascone, 2002, Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate, J Mater Sci Mater Med, 13, 523, 10.1023/A:1014791327253

Leo, 1997, Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involvement of the drug in the cross-linking process, Int J Pharm, 12, 75, 10.1016/S0378-5173(97)00149-X

Verma, 2005, Release kinetics from bio-polymeric nanoparticles encapsulating protein synthesis inhibitor–Cycloheximide, for possible therapeutic applications, Curr Pharm Biotechnol, 6, 121, 10.2174/1389201053642349

Yeh, 2005, Formulating paclitaxel in nanoparticles alters its disposition, Pharm Res, 22, 867, 10.1007/s11095-005-4581-4

Bajpai, 2006, Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate, J Mater Sci Mater Med, 17, 345, 10.1007/s10856-006-8235-9

Sham, 2004, Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung, Int J Pharm, 28, 457, 10.1016/j.ijpharm.2003.09.041

Truong-Le, 1999, Gene transfer by DNA-gelatin nanospheres, Arch Biochem Biophys, 361, 47, 10.1006/abbi.1998.0975

Kaul, 2005, Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)–modified gelatin nanoparticles, J Pharm Sci, 94, 184, 10.1002/jps.20216

Kaul, 2005, Tumor-targeted gene delivery using poly(ethylene glycol)–modified gelatin nanoparticles: in vitro and in vivo studies, Pharm Res, 22, 951, 10.1007/s11095-005-4590-3

Balthasar, 2005, Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes, Biomaterials, 26, 2723, 10.1016/j.biomaterials.2004.07.047

Dinauer, 2005, Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes, Biomaterials, 26, 5898, 10.1016/j.biomaterials.2005.02.038

Li, 1998, Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method, J Microencapsul, 15, 163, 10.3109/02652049809006846

Coester, 2000, Gelatin nanoparticles by two-step desolvation—a new preparation method, surface modifications and cell uptake, J Microencapsul, 17, 187, 10.1080/026520400288427

Leo, 1999, Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticles conjugates, Int J Pharm, 180, 23, 10.1016/S0378-5173(98)00401-3

Echevarrya, 1998, High-performance liquid chromatographic determination of amphotericin B in plasma and tissue application to pharmacokinetic and tissue distribution studies in rats, J Chromatogr A, 819, 171, 10.1016/S0021-9673(98)00425-7

Singhai, 1997, Evaluation of an aqueous injection of ketoprofen, Die Pharmazie, 52, 149

Marcondes, 2000, Acute Trypanosoma cruzi infection is associated with anemia, thrombocytopenia, leukopenia, and bone marrow hypoplasia: reversal by nifurtimox treatment, Microbes Infect, 2, 347, 10.1016/S1286-4579(00)00333-6

Azarmi, 2006, Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells, J Pharm Pharmaceut Sci, 9, 124

Mazerski, 1990, Influence of net charge on the aggregation and solubility on aggregation and solubility behaviour of amphotericin B and its derivatives in aqueous media, Eur Biophys J, 18, 1, 10.1007/BF02427375

Legrand, 1992, Effect of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes, Antimicrob Agents Chemother, 36, 2518, 10.1128/AAC.36.11.2518

Saxena, 2005, Effect of molecular weight heterogeneity on drug encapsulation efficiency of gelatin nano-particles, Coll Surf B: Biointerfaces, 45, 42, 10.1016/j.colsurfb.2005.07.005

Vandervoort, 2004, Preparation and evaluation of drug loaded gelatin nanoparticles for topical ophthalmic use, Eur J Pharm Biopharm, 57, 251, 10.1016/S0939-6411(03)00187-5